Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy. - Kennedy VE; Peretz CAC; Walia A; Chyla B; Sun Y; Hill JE; Tran E; Koh AD; Ferng TT; Pintar S; Jones M; Popescu B; et al. (Blood, 2026)